Prediction of infusion capacity to deliver Alzheimer's disease treatments in the United States relative to expected demand

BackgroundCapacity to deliver intravenous Alzheimer's disease (AD) treatments could constitute an obstacle to access in addition to AD specialist and PET scan capacity.ObjectiveWe aim to estimate the overall capacity for AD treatment infusions compared to expected demand in the United States.MethodsWe used published data and a survey of infusion sites to estimate the capacity to deliver AD treatments in physician offices, hospitals, standalone centers and at patients' homes from 2024 to 2033 relative to demand.ResultsCapacity for intravenous AD treatments is predicted to increase from 370,000 in 2024 to 5.2 million infusions in 2033. Nevertheless, a significant shortfall of over 13 million infusions remains in 2033, which would imply delayed access for 2.2 million patients.ConclusionsLimited infusion capacity could impede AD treatment access and result in avoidable disability progression. Expansion of capacity is needed in the short run until treatments with alternative routes of administration become available.